Mirikizumab Improves Quality of Life in Patients With Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study

被引：0
|
作者：
Lee, Scott D. [1 ]
Vermeire, Severine [2 ]
Ungaro, Ryan C. [3 ]
Durand, Frederick [4 ]
Morris, Nathan [4 ]
Yu, Guanglei [4 ]
Vadhariya, Aisha [4 ]
Traxler, Kristina [4 ]
Fisher, Deborah A. [5 ]
Long, Millie D. [6 ]
机构：
[1] Univ Washington, Med Ctr, Digest Hlth Ctr, Seattle, WA USA
[2] Univ Hosp Leuven, Leuven, Belgium
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Eli Lilly & Co, Indianapolis, IN USA
[5] Eli Lilly & Co, Raleigh, NC USA
[6] Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001035112.50210.ab
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1436
引用
收藏
页码：S1031 / S1032
页数：2
相关论文
共 50 条
  • [21] MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Reguiro, Miguel D.
    Fischer, Monika
    Rubin, David T.
    Shan, Mingyang
    Deckard, Deanilee
    Pollack, Paul
    Hunter, Theresa
    Chan, Lai Shan
    Hindryckx, Pieter
    GASTROENTEROLOGY, 2021, 160 (06) : S354 - S355
  • [22] Mirikizumab Sustained Improvement on Fatigue in Patients With Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study at Week 104
    Regueiro, Miguel
    Fischer, Monika
    Bossuyt, Peter
    McGinnis, Kim
    Gibble, Theresa Hunter
    Protic, Marijana
    Panni, Tommaso
    Hibi, Toshifumi
    Rubin, David T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S816 - S816
  • [23] Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn's disease
    Pai, R.
    De Hertogh, G.
    Reinisch, W.
    Harpaz, N.
    Feagan, R.
    Agada, N.
    Pollack, P.
    Chan, L. S.
    Protic, M.
    Magro, F.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S404 - S406
  • [24] Mirikizumab Pharmacokinetics and Exposure-Response Relationships in Patients With Moderately to Severely Active Crohn's Disease in Phase 2 and 3 Studies
    Chua, Laiyi
    Otani, Yuki
    Friedrich, Stuart
    Durand, Frederick
    Zhang, Xin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1056 - S1056
  • [25] Impact of mirikizumab therapy on histological measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn's disease
    Leong, R.
    Pai, R.
    De Hertogh, G.
    Reinisch, W.
    Harpaz, N.
    Feagan, B. G.
    Agada, N.
    Pollack, P.
    Chan, L-S
    Protic, M.
    Magro, F.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 131 - 131
  • [26] Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
    Sands, Bruce E.
    Feagan, Brian G.
    Gibble, Theresa Hunter
    Traxler, Kristina A.
    Morris, Nathan
    Eastman, William J.
    Schreiber, Stefan
    Jairath, Vipul
    Long, Millie D.
    Armuzzi, Alessandro
    CROHNS & COLITIS 360, 2023, 5 (04)
  • [27] Etrasimod for Moderately to Severely Active Crohn's Disease: Results From the Extension Period of a Phase 2 Study
    D'Haens, Geert R.
    Dubinsky, Marla C.
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    Sands, Bruce E.
    Yarur, Andres J.
    Chiorean, Michael V.
    Modesto, Irene
    Branquinho, Diogo
    McDonnell, Aoibhinn
    Kudela, Maria
    Villa-Caballero, Leonel
    Gu, Guibao
    Tan, Huaming
    Su, Chinyu
    Schreiber, Stefan
    Feagan, Brian G.
    Vermeire, Severine
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S767 - S768
  • [28] EFFICACY, SAFETY, TOLERABILITY OF USTEKINUMAB IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM UNISTAR, A PHASE 1 STUDY
    Rosh, Joel R.
    Turner, Dan
    Griffiths, Anne M.
    Jacobstein, Douglas
    Adedokun, Omoniyi J.
    Padgett, Lakshmi
    Terry, Natalie A.
    O'Brien, Christopher D.
    Hyams, Jeffrey S.
    GASTROENTEROLOGY, 2020, 158 (06) : S235 - S236
  • [29] Pharmacokinetics of ustekinumab in children and adolescents with moderately to severely active Crohn's disease: Results from UniStar, a phase 1 study
    Adedokun, O.
    Hyams, J.
    Turner, D.
    Griffiths, A.
    Terry, N.
    Padgett, L.
    Jacobstein, D.
    O'Brien, C.
    Rosh, J.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S539 - S540
  • [30] Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Results from, UniStar, a phase 1 study
    Rosh, J.
    Turner, D.
    Griffiths, A.
    Jacobstein, D.
    Adedokun, O.
    Padgett, L.
    Terry, N.
    O'Brien, C.
    Hyams, J.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S107 - S109
12345